<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7294518\results\search\tropicalVirus\results.xml">
  <result pre="pmcid: 72945181772 doi: 10.1007/s11262-020-01772-2 : Short Report Rapid decline of" exact="Zika" post="virus NS1 antigen-specific antibody responses, northeastern Brazil Moreira-SotoAndres1de Souza"/>
  <result pre="To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Abstract" exact="Zika" post="virus (ZIKV) is a positive-stranded RNA virus within the"/>
  <result pre="within the Flaviviridae family. After decades of circulation in Asia," exact="ZIKV" post="was introduced to Brazil in 2014–2015, associated with a"/>
  <result pre="in congenital malformations. Unlike the genetically related dengue virus (DENV)," exact="ZIKV" post="constitutes only one serotype. Although assumed that ZIKV infection"/>
  <result pre="virus (DENV), ZIKV constitutes only one serotype. Although assumed that" exact="ZIKV" post="infection may engender lifelong immunity, the long-term kinetics of"/>
  <result pre="ZIKV infection may engender lifelong immunity, the long-term kinetics of" exact="ZIKV" post="antibody responses are unclear. We assessed long-term kinetics of"/>
  <result pre="ZIKV antibody responses are unclear. We assessed long-term kinetics of" exact="ZIKV" post="NS1-IgG response in 144 individuals from 3 different subpopulations:"/>
  <result pre="tested in 2016 and retested 1.5–2 years after the 2015–2016" exact="ZIKV" post="epidemic in Salvador de Bahia, Brazil, using a widely"/>
  <result pre="(56/144, CI 31.3–47.0%) 1.5–2 years later. In addition, the median" exact="ZIKV" post="NS1-ELISA reactivity for individuals that remained positive in both"/>
  <result pre="− 6.1; p &amp;lt; 0.001) irrespective of the subpopulation analyzed. Initial 2016" exact="DENV" post="antibody response was non-significant between groups, suggesting comparable DENV"/>
  <result pre="2016 DENV antibody response was non-significant between groups, suggesting comparable" exact="DENV" post="background. The high 20.6% seroreversion suggest that widely used"/>
  <result pre="tests may fail to account a considerable proportion of past" exact="ZIKV" post="infections in flavivirus endemic countries. In addition, ZIKV immunity"/>
  <result pre="of past ZIKV infections in flavivirus endemic countries. In addition," exact="ZIKV" post="immunity might be shorter-lived than previously thought, which may"/>
  <result pre="be shorter-lived than previously thought, which may contribute to local" exact="ZIKV" post="resurgence once individual immune responses wane sufficiently to reduce"/>
  <result pre="community protective immunity in addition to birth and migration. Keywords" exact="Zika" post="virus Flavivirus Serology Antigens Funding http://dx.doi.org/10.13039/501100007601Horizon 2020 734548DrexlerJan Felix"/>
  <result pre="Felix Open access funding provided by Projekt DEAL Introduction The" exact="Zika" post="virus (ZIKV) is an enveloped positive-stranded RNA virus belonging"/>
  <result pre="dengue virus (DENV), which occurs as four distinct serotypes globally," exact="ZIKV" post="represents only a single serotype to which both the"/>
  <result pre="to which both the African and the Asian lineages of" exact="ZIKV" post="belong [1, 2]. The ZIKV genome encompasses about 10.7"/>
  <result pre="and the Asian lineages of ZIKV belong [1, 2]. The" exact="ZIKV" post="genome encompasses about 10.7 kb containing two non-coding regions"/>
  <result pre="IgG antibodies, since viremia is usually low and transient [4]." exact="ZIKV" post="serologic diagnosis is mostly based on antibodies against two"/>
  <result pre="protein, therefore its wide use in flavivirus serologic tests [8]." exact="ZIKV" post="was first detected in 1947 in Uganda [9]. Later"/>
  <result pre="first detected in 1947 in Uganda [9]. Later in 2007," exact="ZIKV" post="emerged in the Pacific island of Yap, in 2013"/>
  <result pre="63% in mainland America, specifically Brazil [5, 13, 14]. If" exact="ZIKV" post="confers long-lasting immunity, high exposure could create sufficient herd"/>
  <result pre="Latin American countries, cocirculation of other flaviviruses such as DENV," exact="Yellow fever" post="virus, Bussuquara, Cacipacoré, Ilhéus, Rocio and Saint Louis encephalitis"/>
  <result pre="kinetics [15–17]. Nonetheless, long-term antibody kinetics of individuals infected with" exact="ZIKV" post="in Brazil are largely unknown. Here, we conducted a"/>
  <result pre="Here, we conducted a prospective observational cohort study monitoring putative" exact="ZIKV" post="circulation and antibody responses over time of individuals infected"/>
  <result pre="circulation and antibody responses over time of individuals infected with" exact="ZIKV" post="in the metropolitan region of Salvador, Brazil. Results and"/>
  <result pre="between February and May 2016 during the end of the" exact="ZIKV" post="epidemic [5]. Samples belong to three different subpopulations: immunologically"/>
  <result pre="by RT-PCR. Although there was no RT-PCR confirmation of acute" exact="ZIKV" post="infection, it is likely that ZIKV antibody responses are"/>
  <result pre="RT-PCR confirmation of acute ZIKV infection, it is likely that" exact="ZIKV" post="antibody responses are largely comparable between study participants, since"/>
  <result pre="very similar time span during 2015–2016, due to the ultra-rapid" exact="ZIKV" post="spread in Salvador, northeastern Brazil [5]. Brazil acquired millions"/>
  <result pre="spread in Salvador, northeastern Brazil [5]. Brazil acquired millions of" exact="ZIKV" post="NS1 antigen-based indirect ELISA tests (Euroimmun, Lübeck, Germany) for"/>
  <result pre="the paired serum samples from 2016 [5] and 2017–2018. The" exact="ZIKV" post="seropositivity in the first timepoint in 2016 reached 59.0%"/>
  <result pre="subpopulation seroconverted 2 years later, consistent with near-complete lack of" exact="ZIKV" post="activity in northeastern Brazil after the large initial outbreak"/>
  <result pre="CI 14.9–28.4) that were seropositive in 2016 were seronegative for" exact="ZIKV" post="in 2017–2018, the majority of which (n = 25; 83.3%) were"/>
  <result pre="in HIV-positive patients (Fisher, p = 0.03) (Fig. 1c). Fig. 1 a" exact="Zika" post="virus NS1-IgG seropositivity in 2016 (shown in black) and"/>
  <result pre="patients analyzed for the prospective study. b Comparison between the" exact="ZIKV" post="NS1-specific IgG ratios during the epidemic (2016) and follow-up"/>
  <result pre="the individuals whose value of the ratio decreased (below). c" exact="Zika" post="virus NS1–IgG ratio per subpopulation. Colors as in b."/>
  <result pre="virus NS1–IgG ratio per subpopulation. Colors as in b. d" exact="Dengue" post="IgG ratios in 2016 between patients that remained positive"/>
  <result pre="timepoints (–). Colors as in b. n.s. not significant. e" exact="Zika" post="virus specific plaque reduction neutralization test (PRNT). Double asterisk"/>
  <result pre="(PRNT). Double asterisk denotes p &amp;lt; 0,001. Colors as in b. f" exact="Zika" post="virus IgG ratios in 2016. Colors as in b."/>
  <result pre="cross-reactive antibodies elicited by prior infection with flaviviruses other than" exact="ZIKV" post="might have elicited false-positive ZIKV results during first testing."/>
  <result pre="infection with flaviviruses other than ZIKV might have elicited false-positive" exact="ZIKV" post="results during first testing. Cross-reactivity of dengue-specific IgG with"/>
  <result pre="ZIKV results during first testing. Cross-reactivity of dengue-specific IgG with" exact="ZIKV" post="NS1 antigen has been well documented, ranging from 83.3%"/>
  <result pre="infections [20]. If this was the case, patients that are" exact="ZIKV" post="antibody positive in both timepoints might show different DENV-reactive"/>
  <result pre="the groups in 2016, suggesting comparable exposure to the hyperendemic" exact="DENV" post="(Fig. 1d). Unfortunately, due to low sample volumes, no"/>
  <result pre="due to low sample volumes, no further test of the" exact="DENV" post="antibody response in 2018 was performed. Next, to assess"/>
  <result pre="was performed. Next, to assess the specificity of the observed" exact="ZIKV" post="reactive antibody responses, samples were analyzed by plaque reduction"/>
  <result pre="described (Fig. 1e) [5]. In total, 30.0% (24/85) of the" exact="ZIKV" post="NS1-ELISA-positive participants in 2016 where positive by PRNT. Compared"/>
  <result pre="seroreverted also had significantly lower PRNT titers (Fig. 1e) and" exact="ZIKV" post="NS1-ELISA ratio (Fig. 1f) at enrollment than patients that"/>
  <result pre="to differences in the time since exposure to the hyperendemic" exact="DENV" post="[21]. On the other hand, it seems unlikely that"/>
  <result pre="in the sera sampled 2 years later during 2018, because" exact="DENV" post="immune responses are usually long-lasting [17, 20]. It thus"/>
  <result pre="infected individuals at much lower magnitude than antibodies against the" exact="ZIKV" post="envelope antigen that also remain elevated for longer periods"/>
  <result pre="Irrespective of the complex underlying reasons, the observed decrease in" exact="ZIKV" post="NS1-specific antibody levels over time was reminiscent of the"/>
  <result pre="in follow-up samples of two different cohorts. First, from RT-PCR-confirmed" exact="ZIKV" post="infections in travelers using the same NS1-based serologic test"/>
  <result pre="patients during a 2-year period, showing a marked decrease in" exact="ZIKV" post="overall seroprevalence in French Polynesia from 37 to 22%"/>
  <result pre="from 24 to 12% [24]. This decrease was observed for" exact="ZIKV" post="and not for DENV, which causes sporadic outbreaks in"/>
  <result pre="DENV, which causes sporadic outbreaks in the Pacific [24]. Similarly," exact="DENV" post="NS1-specific IgG antibodies were readily detected up to three"/>
  <result pre="Those data are not at odds with our results, because" exact="DENV" post="seroprevalence is as high as 80% in northeastern Brazil"/>
  <result pre="80% in northeastern Brazil [5] and individuals frequently have multiple" exact="DENV" post="infections likely boosting NS1-specific immune responses compared to ZIKV,"/>
  <result pre="used, it is possible that future seroprevalence studies will underestimate" exact="ZIKV" post="spread, particularly in immunocompromised populations. This could also be"/>
  <result pre="of the flaviviral serostatus is illustrated by the interaction between" exact="DENV" post="and ZIKV antibodies that may both protect from and"/>
  <result pre="flaviviral serostatus is illustrated by the interaction between DENV and" exact="ZIKV" post="antibodies that may both protect from and enhance subsequent"/>
  <result pre="is largely unknown [16, 17]. Since Brazil has licensed a" exact="DENV" post="vaccine, adequate determination of the ZIKV serostatus and its"/>
  <result pre="Brazil has licensed a DENV vaccine, adequate determination of the" exact="ZIKV" post="serostatus and its potential interplay with DENV vaccination is"/>
  <result pre="determination of the ZIKV serostatus and its potential interplay with" exact="DENV" post="vaccination is crucial. Finally, studies analyzing long-lasting ZIKV-specific immune"/>
  <result pre="Finally, studies analyzing long-lasting ZIKV-specific immune response are needed, as" exact="ZIKV" post="immunity in flavivirus endemic countries might be shorter than"/>
  <result pre="and migration may sufficiently reduce community protective immunity to allow" exact="ZIKV" post="resurgence. Publisher's Note Springer Nature remains neutral with regard"/>
  <result pre="canonical and alternative coding sequencesPLoS ONE2015102e011784910.1371/journal.pone.011784925719412 2.DowdKADeMasoCRPelcRSSpeerSDSmithARYGooLPlattDJMascolaJRGrahamBSMulliganMJDiamondMSLedgerwoodJEPiersonTCBroadly neutralizing activity of" exact="Zika" post="virus-immune sera identifies a single viral serotypeCell Rep20161661485149110.1016/j.celrep.2016.07.04927481466 3.KunoGChangGJFull-length"/>
  <result pre="Rep20161661485149110.1016/j.celrep.2016.07.04927481466 3.KunoGChangGJFull-length sequencing and genomic characterization of Bagaza, Kedougou, and" exact="Zika" post="virusesAdv Virol20071524687696 4.BozzaFAMoreira-SotoARockstrohAFischerCNascimentoADCalheirosASDrostenCBozzaPTSouzaTMLUlbertSDrexlerJFDifferential shedding and antibody kinetics of Zika"/>
  <result pre="and Zika virusesAdv Virol20071524687696 4.BozzaFAMoreira-SotoARockstrohAFischerCNascimentoADCalheirosASDrostenCBozzaPTSouzaTMLUlbertSDrexlerJFDifferential shedding and antibody kinetics of" exact="Zika" post="and Chikungunya virusesBrazil Emerg Infect Dis201925231131510.3201/eid2502.18016630666934 5.NettoEMMoreira-SotoAPedrosoCHoserCFunkSKucharskiAJRockstrohAKummererBMSampaioGSLuzEVazSNDiasJPBastosFACabralRKistemannTUlbertSde LamballerieXJaenischTBradyOJDrostenCSarnoMBritesCDrexlerJFHigh Zika"/>
  <result pre="virusesAdv Virol20071524687696 4.BozzaFAMoreira-SotoARockstrohAFischerCNascimentoADCalheirosASDrostenCBozzaPTSouzaTMLUlbertSDrexlerJFDifferential shedding and antibody kinetics of Zika and" exact="Chikungunya" post="virusesBrazil Emerg Infect Dis201925231131510.3201/eid2502.18016630666934 5.NettoEMMoreira-SotoAPedrosoCHoserCFunkSKucharskiAJRockstrohAKummererBMSampaioGSLuzEVazSNDiasJPBastosFACabralRKistemannTUlbertSde LamballerieXJaenischTBradyOJDrostenCSarnoMBritesCDrexlerJFHigh Zika virus seroprevalence"/>
  <result pre="of Zika and Chikungunya virusesBrazil Emerg Infect Dis201925231131510.3201/eid2502.18016630666934 5.NettoEMMoreira-SotoAPedrosoCHoserCFunkSKucharskiAJRockstrohAKummererBMSampaioGSLuzEVazSNDiasJPBastosFACabralRKistemannTUlbertSde LamballerieXJaenischTBradyOJDrostenCSarnoMBritesCDrexlerJFHigh" exact="Zika" post="virus seroprevalence in Salvador, Northeastern Brazil limits the potential"/>
  <result pre="MartiniqueBlood2017129226326610.1182/blood-2016-09-73798127827826 15.FigueiredoLTMThe Brazilian flavivirusesMicrobes Infect20002131643164910.1016/S1286-4579(00)01320-411113383 16.FischerCDrostenCDrexlerJFThe difficulties in obtaining reliable" exact="Zika" post="virus diagnosticsLancet Infect Dis201919324024110.1016/S1473-3099(19)30049-030833056 17.OliveiraRAde Oliveira-FilhoEFFernandesAIBritoCAMarquesETTenorioMCGilLHPrevious dengue or Zika"/>
  <result pre="reliable Zika virus diagnosticsLancet Infect Dis201919324024110.1016/S1473-3099(19)30049-030833056 17.OliveiraRAde Oliveira-FilhoEFFernandesAIBritoCAMarquesETTenorioMCGilLHPrevious dengue or" exact="Zika" post="virus exposure can drive to infection enhancement or neutralisation"/>
  <result pre="Inst Oswaldo Cruz2019114e19009810.1590/0074-0276019009831411310 18.CormanVMRascheABarontiCAldabbaghSCadarDReuskenCBPasSDGoorhuisASchinkelJMolenkampRKummererBMBleickerTBruninkSEschbach-BludauMEis-HubingerAMKoopmansMPSchmidt-ChanasitJGrobuschMPde LamballerieXDrostenCDrexlerJFAssay optimization for molecular detection of" exact="Zika" post="virusBull World Health Organ2016941288089210.2471/BLT.16.17595027994281 19.BalmasedaAStettlerKMedialdea-CarreraRColladoDJinXZambranaJVJaconiSCameroniESaborioSRovidaFPercivalleEIjazSDicksSUshiro-LumbIBarzonLSiqueiraPBrownDWGBaldantiFTedderRZambonMde FilippisAMBHarrisECortiDAntibody-based assay discriminates Zika"/>
  <result pre="of Zika virusBull World Health Organ2016941288089210.2471/BLT.16.17595027994281 19.BalmasedaAStettlerKMedialdea-CarreraRColladoDJinXZambranaJVJaconiSCameroniESaborioSRovidaFPercivalleEIjazSDicksSUshiro-LumbIBarzonLSiqueiraPBrownDWGBaldantiFTedderRZambonMde FilippisAMBHarrisECortiDAntibody-based assay discriminates" exact="Zika" post="virus infection from other flavivirusesProc Natl Acad Sci USA2017114318384838910.1073/pnas.170498411428716913"/>
  <result pre="infectionsJ Virol Methods2018257626810.1016/j.jviromet.2018.04.00929684416 21.PedrosoCFischerCFeldmannMSarnoMLuzEMoreira-SotoACabralRNettoEMBritesCKummererBMDrexlerJFCross-protection of dengue virus infection against congenital" exact="Zika" post="syndrome, Northeastern BrazilEmerg Infect Dis20192581485149310.3201/eid2508.19011331075077 22.HillSCVasconcelosJNetoZJandondoDZe-ZeLAguiarRSXavierJThezeJMirandelaMMicolo CandidoALVazFSebastiaoCDSWuCHKraemerMUGMeloASchamber-ReisBLFde AzevedoGSTanuriAHigaLMClementeCda SilvaSPda"/>
  <result pre="22.HillSCVasconcelosJNetoZJandondoDZe-ZeLAguiarRSXavierJThezeJMirandelaMMicolo CandidoALVazFSebastiaoCDSWuCHKraemerMUGMeloASchamber-ReisBLFde AzevedoGSTanuriAHigaLMClementeCda SilvaSPda SilvaCDClaroIMQuibucoDDomingosCPocongoBWattsAGKhanKAlcantaraLCJSabinoECLackritzEPybusOGAlvesMJAfonsoJFariaNREmergence of the Asian lineage of" exact="Zika" post="virus in Angola: an outbreak investigationLancet Infect Dis201919101138114710.1016/S1473-3099(19)30293-231559967 23.LustigYCotarAICeianuCSCastillettiCZelenaHBurdinoEvan"/>
  <result pre="in Angola: an outbreak investigationLancet Infect Dis201919101138114710.1016/S1473-3099(19)30293-231559967 23.LustigYCotarAICeianuCSCastillettiCZelenaHBurdinoEvan TienenCAvsicTAaronsEReuskenCLack of" exact="Zika" post="virus antibody response in confirmed patients in non-endemic countriesJ"/>
  <result pre="French Polynesia and FijieLife20202894846010.7554/eLife.48460 25.MarquesETADrexlerJFComplex Scenario of Homotypic and Heterotypic" exact="Zika" post="Virus Immune EnhancementmBio2019105e01849-1910.1128/mBio.01849-1931481385"/>
 </snippets>
</snippetsTree>
